The COVID-19 pandemic triggered unexpected challenges in the business environment prompting pharmaceutical companies to accelerate the adoption of digital transformation…
The COVID-19 pandemic has led to an increase in investments in digital transformation and emerging technologies to deal with the…
Clinical-stage biopharmaceutical company Senhwa Biosciences has enrolled the first patient in a Phase II trial of its investigational drug, Silmitasertib, for treating hospitalised Covid-19 patients.…
Eli Lilly and Company has announced results from the Phase III BLAZE-2 trial, which showed bamlanivimab (LY-CoV555) significantly lowered the risk of contracting symptomatic Covid-19…
Moderna has dosed the first participant in the Phase I/II study of its Covid-19 vaccine candidate, (mRNA-1273 or TAK-919), in…
Digital transformation has become the need of the hour due to the COVID-19 pandemic. While some organisations adapted to it…
Digital transformation is prodding the organisations to change the way things used to work and require greater resource allocation. GlobalData…
Cloud-based solutions provider Reify Health has announced the availability of its patient enrollment performance management platform, StudyTeam, to clinical research…
Digital transformation has been one of the key strategic initiatives being undertaken by the pharmaceutical industry in recent years. The…
With the increase in logistical and recruitment challenges for conducting clinical trials amid the COVID-19 pandemic, the pharmaceutical and healthcare…
When it comes to clinical trial submission, one of the most significant standards is the Analysis Data Model (ADaM), as…
Small animal optical imaging provides oncology researchers with the ability to perform non-invasive longitudinal monitoring of disease progression, detection of…
GEMTESA® (vibegron) is the first new oral medication indicated for the treatment of overactive bladder (OAB) with signs of urge…
OpenClinica is pleased to announce that it will be included in public television series In Depth, exhibiting its clinical trials…
